Goprazol

Goprazol is a pharmaceutical product that contains the active ingredient omeprazole, a proton pump inhibitor, marketed in the European Union. It is supplied as an oral dosage form intended for systemic use. Omeprazole works by inhibiting the gastric H+/K+ ATPase pump, thereby decreasing stomach acid production. Goprazol is classified as a gastro‑protective agent and is available by prescription or over‑the‑counter in many local regulations.

Goprazol is indicated for several acid‑related gastrointestinal conditions where reduction of gastric acidity is required.

- Gastroesophageal reflux disease (GERD) – relief of heartburn and esophageal irritation. - Peptic ulcer disease – promotes healing of gastric and duodenal ulcers. - Helicobacter pylori eradication regimens – used in combination with antibiotics. - Zollinger‑Ellison syndrome – management of hypersecretory gastric acid. - Prevention of NSAID‑induced gastric ulcers – when co‑prescribed with non‑steroidal anti‑inflammatory drugs.

The safety profile of Goprazol includes both frequently observed and less common adverse reactions.

Common: - Headache. - Diarrhea. - Nausea or vomiting. - Abdominal pain or flatulence.

Serious: - Severe allergic reactions such as rash, itching, swelling, or difficulty breathing. - Clostridioides difficile‑associated diarrhea. - Low magnesium levels (hypomagnesemia) with prolonged use.

Before starting Goprazol, certain precautions should be considered to ensure safe and effective use.

- Assess renal or hepatic impairment, as dose adjustment may be needed. - Use with caution in patients with a history of osteoporosis or fracture risk due to possible reduced calcium absorption. - Evaluate for potential vitamin B12 deficiency with long‑term therapy. - Monitor for signs of infection, especially gastrointestinal infections, during prolonged treatment. - Consider pregnancy and breastfeeding status; discuss risks with a healthcare professional. - Review any history of hypersensitivity to omeprazole or other proton pump inhibitors.

Goprazol may interact with other medicines, influencing their effectiveness or safety.

Avoid: - Co‑administration with atazanavir or nelfinavir, as reduced antiviral exposure may occur. - Use with clopidogrel, which may diminish antiplatelet activity.

Use with caution: - Concomitant use of warfarin, as it may increase bleeding risk. - Combination with methotrexate, especially high‑dose, may raise methotrexate levels. - Concurrent use of digoxin, where absorption may be increased.